Japan Hemoglobinopathies Market Size & Outlook, 2022-2030

The hemoglobinopathies market in Japan is expected to reach a projected revenue of US$ 1,206.3 million by 2030. A compound annual growth rate of 10.5% is expected of Japan hemoglobinopathies market from 2023 to 2030.
Revenue, 2022 (US$M)
$540.8
Forecast, 2030 (US$M)
$1,206.3
CAGR, 2023 - 2030
10.5%
Report Coverage
Japan

Japan hemoglobinopathies market highlights

  • The Japan hemoglobinopathies market generated a revenue of USD 540.8 million in 2022 and is expected to reach USD 1,206.3 million by 2030.
  • The Japan market is expected to grow at a CAGR of 10.5% from 2023 to 2030.
  • In terms of segment, sickle cell disease was the largest revenue generating disease type in 2022.
  • Sickle cell disease is the most lucrative disease type segment registering the fastest growth during the forecast period.


Hemoglobinopathies market data book summary

Market revenue in 2022USD 540.8 million
Market revenue in 2030USD 1,206.3 million
Growth rate10.5% (CAGR from 2022 to 2030)
Largest segmentSickle cell disease
Fastest growing segmentSickle cell disease
Historical data2018 - 2021
Base year2022
Forecast period2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationThalassemia, Sickle cell disease, Other Hb Variants
Key market players worldwideSangamo Therapeutics Inc, Global Blood Therapeutics, Bluebird bio Inc, Emmaus Life Sciences Inc, Pfizer Inc, Novartis AG ADR, Prolong Pharmaceuticals, Bioverativ, Gamida Cell, Bristol-Myers Squibb Co


Other key industry trends

  • In terms of revenue, Japan accounted for 3.5% of the global hemoglobinopathies market in 2022.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China hemoglobinopathies market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,635.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hemoglobinopathies Market Companies

Name Profile # Employees HQ Website

Japan hemoglobinopathies market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemoglobinopathies market will help companies and investors design strategic landscapes.


Sickle cell disease was the largest segment with a revenue share of 59.28% in 2022. Horizon Databook has segmented the Japan hemoglobinopathies market based on thalassemia, sickle cell disease, other hb variants covering the revenue growth of each sub-segment from 2018 to 2030.


Increasing focus on the development of new therapies for the treatment of hemoglobinopathies is expected to drive the growth of the market in Japan. According to a 2017 study conducted by University of New South Wales (UNSW) in partnership with RIKEN BioResource Center and Japanese Red Cross Society, a benign genetic mutation called British-198 mutation was introduced in human cells to facilitate fetal hemoglobin production.

Fetal hemoglobin can help in compensating the lack of normal adult hemoglobin, making the disease milder in patients affected by it. Better access to healthcare in the country is also expected to improve screening and treatment for SCD & thalassemia. The recent SARS-CoV-2 pandemic is not expected to impact the supply chain of SCD drugs.

Reasons to subscribe to Japan hemoglobinopathies market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan hemoglobinopathies market databook

  • Our clientele includes a mix of hemoglobinopathies market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan hemoglobinopathies market , including forecasts for subscribers. This country databook contains high-level insights into Japan hemoglobinopathies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan hemoglobinopathies market size, by disease type, 2018-2030 (US$M)

Japan Hemoglobinopathies Market Outlook Share, 2022 & 2030 (US$M)

Japan hemoglobinopathies market size, by disease type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more